UCB has
announced its financial results for 2011, reporting an annual revenue total of
3.25 billion euros (2.7 billion pounds) that reflected year-on-year growth of
one percent.
The pharmaceutical company's improved performance over the last year is attributable to the rising uptake of newer medicines such as Cimzia, Vimpat and Neupro, all of which saw double-digit surges in sales.
Growth in these areas helped UCB to offset the impact of patent expiries on its mature product portfolio, while the anti-epileptic treatment Keppra continued to be resilient in international territories, despite its loss of market exclusivity in the US.
Over the coming year, UCB intends to file for new approvals for Cimzia, while continuing the clinical development of other new treatments.
Roch Doliveux, chief executive officer of UCB, said: "Our solid 2011 performance, the momentum of our new medicines, new geographies and our promising pipeline provide a platform for future sustainable growth without major patent expiries ahead."
Last month, the company reported positive data from a new Cimzia trial, showing its efficacy in a new indication against rheumatoid arthritis.
The pharmaceutical company's improved performance over the last year is attributable to the rising uptake of newer medicines such as Cimzia, Vimpat and Neupro, all of which saw double-digit surges in sales.
Growth in these areas helped UCB to offset the impact of patent expiries on its mature product portfolio, while the anti-epileptic treatment Keppra continued to be resilient in international territories, despite its loss of market exclusivity in the US.
Over the coming year, UCB intends to file for new approvals for Cimzia, while continuing the clinical development of other new treatments.
Roch Doliveux, chief executive officer of UCB, said: "Our solid 2011 performance, the momentum of our new medicines, new geographies and our promising pipeline provide a platform for future sustainable growth without major patent expiries ahead."
Last month, the company reported positive data from a new Cimzia trial, showing its efficacy in a new indication against rheumatoid arthritis.